Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response

Atte Valli; Krista Kuuliala; Anniina Virtanen; Antti Kuuliala; Maaria Palmroth; Ritva Peltomaa; Krista-Liisa Vidqvist; Marjatta Leirisalo-Repo; Olli Silvennoinen; Pia Isomäki

doi:10.1093/cei/uxac085

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response

Atte Valli, Krista Kuuliala, Anniina Virtanen, Antti Kuuliala, Maaria Palmroth, Ritva Peltomaa, Krista-Liisa Vidqvist, Marjatta Leirisalo-Repo, Olli Silvennoinen, Pia Isomäki

Research output: Contribution to journal › Article › Scientific › peer-review

Original language	English
Journal	Clinical and Experimental Immunology
Volume	210
Issue number	2
Pages (from-to)	141-150
Number of pages	10
ISSN	0009-9104
DOIs	https://doi.org/10.1093/cei/uxac085
Publication status	Published - 15 Dec 2022
MoE publication type	A1 Journal article-refereed

Fields of Science

JANUS KINASE INHIBITOR
JAK INHIBITOR
METHOTREXATE
ACTIVATION
INTERLEUKIN-6
ETANERCEPT
EXPRESSION
CP-690,550
THERAPY
STAT
Therapy
Activation
Jak inhibitor
Oncostatin m
Interleukin-6
Etanercept
Expression
Cp-690,550
Methotrexate
Janus kinase inhibitor
3121 General medicine, internal medicine and other clinical medicine
3111 Biomedicine

Access to Document

10.1093/cei/uxac085

uxac085Final published version, 593 KBLicence: CC BY

Cite this

Valli, A., Kuuliala, K., Virtanen, A., Kuuliala, A., Palmroth, M., Peltomaa, R., Vidqvist, K.-L., Leirisalo-Repo, M., Silvennoinen, O., & Isomäki, P. (2022). Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response. Clinical and Experimental Immunology, 210(2), 141-150. https://doi.org/10.1093/cei/uxac085

@article{9749ed09a46a46fb9eb0481b6fe2f963,

title = "Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response",

keywords = "JANUS KINASE INHIBITOR, JAK INHIBITOR, METHOTREXATE, ACTIVATION, INTERLEUKIN-6, ETANERCEPT, EXPRESSION, CP-690,550, THERAPY, STAT, Therapy, Activation, Jak inhibitor, Oncostatin m, Interleukin-6, Etanercept, Expression, Cp-690,550, Methotrexate, Janus kinase inhibitor, 3121 General medicine, internal medicine and other clinical medicine, 3111 Biomedicine",

author = "Atte Valli and Krista Kuuliala and Anniina Virtanen and Antti Kuuliala and Maaria Palmroth and Ritva Peltomaa and Krista-Liisa Vidqvist and Marjatta Leirisalo-Repo and Olli Silvennoinen and Pia Isom{\"a}ki",

year = "2022",

month = dec,

day = "15",

doi = "10.1093/cei/uxac085",

language = "English",

volume = "210",

pages = "141--150",

journal = "Clinical and Experimental Immunology",

issn = "0009-9104",

publisher = "Oxford University Press",

number = "2",

}

Valli, A, Kuuliala, K, Virtanen, A, Kuuliala, A, Palmroth, M, Peltomaa, R, Vidqvist, K-L, Leirisalo-Repo, M , Silvennoinen, O & Isomäki, P 2022, 'Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response', Clinical and Experimental Immunology, vol. 210, no. 2, pp. 141-150. https://doi.org/10.1093/cei/uxac085

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response. / Valli, Atte; Kuuliala, Krista; Virtanen, Anniina et al.
In: Clinical and Experimental Immunology, Vol. 210, No. 2, 15.12.2022, p. 141-150.

Research output: Contribution to journal › Article › Scientific › peer-review

TY - JOUR

T1 - Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response

AU - Valli, Atte

AU - Kuuliala, Krista

AU - Virtanen, Anniina

AU - Kuuliala, Antti

AU - Palmroth, Maaria

AU - Peltomaa, Ritva

AU - Vidqvist, Krista-Liisa

AU - Leirisalo-Repo, Marjatta

AU - Silvennoinen, Olli

AU - Isomäki, Pia

PY - 2022/12/15

Y1 - 2022/12/15

KW - JANUS KINASE INHIBITOR

KW - JAK INHIBITOR

KW - METHOTREXATE

KW - ACTIVATION

KW - INTERLEUKIN-6

KW - ETANERCEPT

KW - EXPRESSION

KW - CP-690,550

KW - THERAPY

KW - STAT

KW - Therapy

KW - Activation

KW - Jak inhibitor

KW - Oncostatin m

KW - Interleukin-6

KW - Etanercept

KW - Expression

KW - Cp-690,550

KW - Methotrexate

KW - Janus kinase inhibitor

KW - 3121 General medicine, internal medicine and other clinical medicine

KW - 3111 Biomedicine

U2 - 10.1093/cei/uxac085

DO - 10.1093/cei/uxac085

M3 - Article

SN - 0009-9104

VL - 210

SP - 141

EP - 150

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

IS - 2

ER -

Valli A, Kuuliala K, Virtanen A, Kuuliala A, Palmroth M, Peltomaa R et al. Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response. Clinical and Experimental Immunology. 2022 Dec 15;210(2):141-150. Epub 2022 Sept 17. doi: 10.1093/cei/uxac085